Medicare AdvantageCoverageMedium impact
MA06.021d, In Vitro Chemosensitivity and Chemoresistance Assays
Independence Blue Cross·Oncology, Pathology·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Policy MA06.021d regarding In Vitro Chemosensitivity and Chemoresistance Assays was reissued effective October 1, 2025. Without access to the full policy text content, the specific coverage changes, billing code impacts, or prior authorization requirements cannot be determined. The billing team must obtain the complete policy document to identify actionable changes.
Action Required
By October 1, 2025: Billing team must obtain the complete text of policy MA06.021d from the provided URL (https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=10&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#medicare-advantage-ma06-021d-in-vitro-chemosensitivity-and-c). Review the full policy content to identify: (1) specific CPT or HCPCS codes affected, (2) prior authorization requirements, (3) coverage limitations, and (4) documentation requirements. Update billing software rules, encounter templates, and staff procedures accordingly. Communicate changes to providers and front-desk staff. Claims submitted without compliance to the reissued policy may be denied or delayed.